Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Wall Street Analysts Comment on Walgreens Boots Earnings

Published 30/06/2022, 16:50
Updated 30/06/2022, 16:50
© Reuters.

By Sam Boughedda

Walgreens Boots Alliance (NASDAQ:WBA) shares have tumbled Thursday, down 5%, after the company reported earnings before the open.

The company reported third-quarter earnings per share of $0.96, bettering analyst estimates of $0.91 by $0.05. Revenue for the quarter came in at $32.6 billion, also beating the consensus estimate of $32.01 billion.

Both sales and profit decreased year over year due to weakening Covid-19 vaccination demand, investments in its health care business, and an opioid settlement with Florida.

Following the earnings release, analysts at Mizuho and Credit Suisse (SIX:CSGN) released notes:

On the results, Mizuho analyst Ann Hynes, who has a Neutral rating and a $49 price target on the stock, said: "The quarter was impacted by a $683mm charge related to the opioid settlement with Florida. WBA administered 4.7mm COVID vaccines and 3.9mm tests in FQ3. The company maintained FY22 adjusted EPS growth guidance of low-single-digit, in-line with our expectations. WBA raised expectations for the base business from +6%-8% growth to +7%-9% growth due to strong US front store performance, offset by higher growth investments. Free cash flow was $1.3bn in the quarter."

Hynes added, regarding the company's decision to shelve the Boots sale, that they suspect the market backdrop is the main driver of the decision.

Credit Suisse analyst A.J. Rice, who has a Neutral rating and $52 per share price target on Walgreens Boots, stated: "Total adj EPS from continuing ops decreased 30.0% Y/Y to $0.96 (down 28.9% on a constant currency basis), $0.07/0.04 ahead of CSe/Cons. Sales from continuing ops in 3Q22 decreased 4.2% Y/Y to $32.6 bln (down 2.8% on a constant currency basis), which compares with consensus revs of $32.1 bln and CSe of $31.3 bln."

"The Y/Y decline was due to a 720 basis point impact from the sales decline at AllianceRx Walgreens. This was offset in part by international segment growth of 0.3% (9.3% on a CC basis) to $5.3 bln, reflecting the ongoing recovery in the UK market and growth in the German wholesale business," added Rice.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.